Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are investigating the safety and effectiveness of Fertilo compared to Medicult IVM for in vitro maturation IVM of eggs in women aged 18 to 35. The study aims to find out if Fertilo leads to better pregnancy outcomes, specifically looking at the number of ongoing pregnancies at 12 weeks gestation. This phase III randomized trial compares these two methods to improve infertility treatment. Participants will be randomly assigned to one of two groups. In the first group, immature eggs surrounded by supportive cells are cultured in Fertilo for 30 hours. In the second group, the eggs are cultured in the standard Medicult IVM system for the same duration. After maturation, eggs in both groups are fertilized, grown to the blastocyst stage, frozen, and later transferred for reproductive purposes. During the study, participants will undergo assessments including hormone level measurements, ultrasounds, and sperm analysis for male partners. Researchers will track several outcomes such as egg maturation rate, fertilization success, embryo development, pregnancy rates, and live births. The trial includes safety monitoring and follow-up until at least 12 weeks of pregnancy, with the total study period expected to last until early 2028.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Researchers are evaluating the benefits of combining repetitive Transcranial Magnetic Stimulation rTMS with Cognitive Processing Therapy CPT to treat combat-related Posttraumatic Stress Disorder PTSD symptoms. The study aims to compare PTSD symptom reduction among three groups those receiving rTMS before CPT sessions, those receiving sham rTMS before CPT, and those receiving rTMS alone. Additionally, the study will assess changes in depression, psychosocial functioning, and brain activity using EEG and MRI. Participants will be randomly assigned to one of three treatment groups 1 30 minutes of sham rTMS to the right dorsolateral prefrontal cortex rDLPFC before each of 12 CPT sessions, 2 30 minutes of active 1 Hz rTMS to the rDLPFC before each of 12 CPT sessions, or 3 30 minutes of active 1 Hz rTMS alone once weekly for 12 weeks. The rTMS device delivers magnetic pulses targeting specific brain regions to potentially influence PTSD symptoms. Participants will undergo assessments at baseline, during treatment sessions 5 and 9, and at 1, 6, and 12 months after treatment completion. These evaluations include PTSD symptom severity measures, neuropsychological tests, EEG recordings, and MRI scans. Researchers will monitor treatment effects and safety throughout the study, which lasts up to 12 months post-treatment.
Actively Recruiting
This research aims to collect information on the clinical outcomes and real-world use of OssDsign bone graft substitutes in patients who require spine fusion surgery. The study is a multi-center, prospective, observational registry involving up to 25 sites in the US. It focuses on patients diagnosed with degenerative disc disease or spinal stenosis who undergo spine fusion with OssDsign bone grafts. Participants receive commercially available OssDsign Catalyst bone graft substitutes, which are osteoconductive, resorbable, porous, and made of 100% nano synthetic calcium phosphate. The study will follow patients for up to 24 months 90 days after their index spine fusion surgery where the bone graft was implanted. The primary outcome measured is the rate of bone fusion approximately 12 months after surgery. During the study, participants will undergo clinical and radiographic follow-up evaluations including quality of life questionnaires such as the Oswestry Disability Index, Neck Disability Index, Visual Analog Scale, and Short Form 36 at multiple time points up to 24 months. Neurological function and presence of bone fusion will also be assessed at 6, 12, and 24 months. Safety reviews of device-related adverse events will be conducted throughout the study period.